Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

Key Points

• Theratechnologies Inc. experienced a significant 26.4% decline in short interest, dropping from 310,500 shares to 228,400 shares as of July 31st.
• Several institutional investors have recently increased their stakes in Theratechnologies, including Bank of America, which grew its stake by 1,416.7% during the fourth quarter.
• Theratechnologies reported a loss of $0.09 per share for the last quarter, failing to meet analysts' expectations of a loss of $0.01.

Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) saw a large decline in short interest during the month of July. As of July 31st, there was short interest totaling 228,400 shares, adeclineof26.4% from the July 15th total of 310,500 shares. Based on an average daily trading volume, of 462,000 shares, the short-interest ratio is presently 0.5 days. Approximately0.6% of the shares of the stock are short sold. Approximately0.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 462,000 shares, the short-interest ratio is presently 0.5 days.

Institutional Trading of Theratechnologies

Several institutional investors have recently made changes to their positions in THTX. Stonepine Capital Management LLC raised its position in shares of Theratechnologies by 632.0% during the 2nd quarter. Stonepine Capital Management LLC now owns 189,051 shares of the company's stock valued at $446,000 after buying an additional 163,226 shares during the period. Alberta Investment Management Corp purchased a new stake in shares of Theratechnologies during the 2nd quarter valued at approximately $354,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Theratechnologies during the 2nd quarter valued at approximately $313,000. Rangeley Capital LLC purchased a new stake in shares of Theratechnologies during the 2nd quarter valued at approximately $118,000. Finally, Cyndeo Wealth Partners LLC purchased a new stake in shares of Theratechnologies during the 1st quarter valued at approximately $42,000.

Theratechnologies Price Performance

Shares of THTX stock remained flat at $3.25 during trading on Tuesday. 299,272 shares of the stock traded hands, compared to its average volume of 282,068. The company has a market capitalization of $149.44 million, a price-to-earnings ratio of -17.11 and a beta of 0.52. The firm's 50-day moving average price is $3.01 and its two-hundred day moving average price is $2.43. Theratechnologies has a 1 year low of $1.12 and a 1 year high of $3.26.

Theratechnologies (NASDAQ:THTX - Get Free Report) last released its quarterly earnings results on Wednesday, July 9th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The firm had revenue of $17,729 billion for the quarter, compared to analysts' expectations of $24.30 million. On average, equities analysts forecast that Theratechnologies will post 0.01 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Jones Trading cut Theratechnologies from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 3rd. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy".

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.